Eikon Therapeutics, Inc. Common Stock (EIKN) Stock
Fundamentals
Recent news

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
EIKN

Eikon Therapeutics valued at $860 million in Nasdaq debut
Eikon Therapeutics valued at $860 million in Nasdaq debut
EIKN

Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
EIKN

Eikon Therapeutics targets $908 million valuation in US IPO
Eikon Therapeutics targets $908 million valuation in US IPO
EIKN
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 5 articles
published over the past 14 days
Latest news

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
EIKN

Eikon Therapeutics valued at $860 million in Nasdaq debut
Eikon Therapeutics valued at $860 million in Nasdaq debut
EIKN

Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
EIKN

Eikon Therapeutics targets $908 million valuation in US IPO
Eikon Therapeutics targets $908 million valuation in US IPO
EIKN

Biopharmaceutical firm Eikon Therapeutics files for US IPO
Biopharmaceutical firm Eikon Therapeutics files for US IPO
EIKN
About Eikon Therapeutics, Inc. Common Stock
The company is a late-stage clinical biopharmaceutical organization focused on building a global, fully integrated platform to develop innovative medicines that address serious unmet medical needs. It is led by internationally recognized drug development leaders Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. The company’s vision is to become a generational leader by intentionally integrating traditional biological research with advanced engineering capabilities to accelerate the development of higher-quality medicines. Its initial therapeutic focus is oncology, with a pipeline of drug candidates targeting areas of significant unmet need across large patient populations.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Roger M. Perlmutter M.D., Ph.D. | Chairman, President & CEO | 1952 |
| Mr. Michael A. Klobuchar | Chief Operating Officer | 1976 |
| Dr. Roy D. Baynes FACP, M.D., Ph.D. | Executive VP & Chief Medical Officer | 1955 |
| Dr. Robert Tjian Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1949 |
| Dr. Eric Betzig Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Dr. Alfred Lloyd Bowie Jr., Ph.D. | Treasurer & CFO | 1982 |
| Mr. Russ Berman | Chief Technology Officer | — |
| Dr. Ching-Pin Chang M.D., Ph.D. | Executive VP & Chief Scientific Officer | — |
| Mr. Benjamin Bruno Thorner | Secretary, General Counsel & Chief Business Officer | 1971 |
| Ms. Barbara Howes M.B.A. | Chief People Officer | 1965 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.1 | -28.9 | -4.6 | +12.0 | +20.9 | -24.8 | +14.3 | -27.2 |



